Harvard Bioscience (HBIO) 4.30 $HBIO
Global Transfection Technology (Reagent-based method, Instrument-based method and Virus-based method) Market - Forecast to 2019
M2 - Fri May 09, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h75tdm/transfection) has announced the addition of the "Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Transfection is a process that involves production of genetically modified cells with the delivery of foreign nucleic acid (DNA or RNA) into the cell. There are two types of transfection technologies that include stable and transient. While stable transfection is permanent and the genes are continually expressed even after the host cell replicates, transient transfected genes are expressed for a limited period of time and are not integrated into the host genome. Increasing prevalence of cancer and growing obese population drives the global transfection technology market. In addition, initiatives taken by various government organizations also further accentuates the growth of this market. Transfection technologymarket is segmented mainly by types of method and application. The method segment of the market is classified as reagent-based method, instrument-based method and virus-based method. The reagent-based method is further segmented as lipid mediated transfection (Lipofection), calcium phosphate, cationic polymers, DEAE-dextran, activated dendrimers and magnetic beads. Reagent based transfection technology market is experiencing significant growth owing to cost effectiveness and less complicated methods involved during transfection. Likewise, instrument-based method includes electroporation, biolistic technology, microinjection and laserfection.Instrument-based methods are less time consuming and accurate;these advantages drive the growth of this segment. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Transfection Technology Market, by Methods Chapter 5 Global Transfection Technology Market, By Application Chapter 6 Global Transfection Technology Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Bio-Rad Laboratories, Inc. - Harvard Bioscience, Inc. - Life Technologies Corporation - Lonza Group Ltd. - Merck KGaA - Mirus Bio LLC - Polyplus-transfection S.A. - Promega Corporation - QIAGEN - Roche Holding AG - Sigma-Aldrich Corporation - SignaGen Laboratories - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/h7...ansfection
Harvard Bioscience Reports First Quarter 2014 Results
GlobeNewswire - Thu May 01, 6:02AM CDT
Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today reported financial highlights for the three months ended March 31, 2014.
Electrophoresis Equipment and Supplies Market 2013-2019: Gel Electrophoresis, Capillary Electrophoresis and Electrophoresis Accessories Analysis
M2 - Wed Apr 30, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xwbmkl/electrophoresis) has announced the addition of the "Electrophoresis Equipment and Supplies Market 2013-2019: Gel Electrophoresis, Capillary Electrophoresis and Electrophoresis Accessories Analysis" report to their offering. Electrophoresis is an analytical technique used to separate macromolecules such as nucleic acid fragments, proteins and RNA according to their molecular size and electric charge. Electrophoresis can be classified in two types gel electrophoresis and capillary electrophoresis. Electrophoresis clinical applications can be segmented as diagnostics (protein), hemoglobin analysis and microbial detection. This report studies the global market for electrophoresis equipment and supplies market along with its clinical applications. The market is thus segmented on the basis of technologies and applications. The market for electrophoresis equipment and supplies are also analyzed for four major geographic regions namely North America, Europe, Asia and the rest of the world (RoW) regions. The markets for all these segments is analyzed and estimated in USD million. Each of the segments has been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD million, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for electrophoresis equipment and supplies market. A chapter on recommendations for existing and new entrants is also provided in this report. Some of the major players profiled in this report are BioRad Laboratories, Inc., GE Healthcare Ltd., Hoefer, Inc., Agilent Technologies, Life Technologies Corporation, Thermo Fisher Scientific, Inc. and Danaher Corporation. All these market players are profiled in this report via parameters such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Electrophoresis Equipment and Supplies Market, by Technology, 2013 - 2019 (USD Million) Chapter 5 Global Electrophoresis Equipment and Supplies Market, by Applications, 2013 - 2019 (USD Million) Chapter 6 Global Electrophoresis Equipment and Supplies Market, by Geography, 2013 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - GE Healthcare - Harvard Bioscience, Inc. - Helena Laboratories Corporation - Life Technologies Corporation - Lonza Group - Perkin Elmer, Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/xw...rophoresis
Harvard Bioscience to Present at the Sidoti Micro-Cap Conference on May 9 in New York
GlobeNewswire - Wed Apr 23, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of solutions to advance life science, will present at the Sidoti Ninth Semiannual Micro-Cap Conference in New York City on May 9, 2014.
SeeThruEquity Issues Update on Harvard Bioscience Inc.
ACCESSWIRE - Thu Apr 17, 8:01AM CDT
New York, NY / ACCESSWIRE / April 17, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update note on Harvard Bioscience Inc. (NASDAQ: HBIO) regarding financial and operational results for Q4 2013 and FY 2013.
Harvard Bioscience Schedules First Quarter 2014 Conference Call for May 1, 2014 at 11:00 AM ET
GlobeNewswire - Thu Apr 17, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of solutions to advance life science, will announce results for its first quarter before market trading hours on Thursday, May 1, 2014. A conference call to discuss the company's first quarter is scheduled for that same day at 11:00 AM ET.
I’m Selling Harvard Biosciences
Jim Royal, The Motley Fool - Motley Fool - Thu Mar 27, 3:31PM CDT
My Special Situations portfolio took a stake in Harvard Bioscience before its recently completed spinoff of Harvard Apparatus Regenerative Technology . That was in January of last year, and the combined position has risen about 39%. Not bad....
Harvard Bioscience Names Ronald Aplin to Vice President Global Operations and Quality
GlobeNewswire - Mon Mar 10, 6:13AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately. This is a newly created position.
Nasdaq stocks posting largest volume increases
AP - Mon Mar 03, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Harvard Bioscience Reports Fourth Quarter and Year-End 2013 Results
GlobeNewswire - Thu Feb 27, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of specialized products to advance life science research, today reported financial highlights for the fourth quarter and full year ended December 31, 2013.
Harvard Bioscience Schedules Fourth Quarter and Year-End 2013 Conference Call for February 27, 2014 at 11:00 AM ET
GlobeNewswire - Fri Feb 14, 6:30AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, will announce results for its fourth quarter and year ended December 31, 2013 before market trading hours on Thursday, February 27, 2014. A conference call to discuss the company's fourth quarter and year-end financial results is scheduled for that same day at 11:00 AM ET.
Harvard Bioscience Realigns Global Operations to Create Organizational Efficiencies and Better Position It for Growth
GlobeNewswire - Wed Dec 04, 6:00AM CST
-Reallocating Resources to Higher-Growth Areas-
Upgrade Alert for Harvard Bioscience (HBIO)
Comtex SmarTrend(R) - Wed Nov 27, 7:04AM CST
Harvard Bioscience (NASDAQ:HBIO) was upgraded from Neutral to Buy at Sidoti today. The stock closed yesterday at $4.47 on volume of 393,000 shares, above average daily volume of 202,000. In the past 52 weeks, Harvard Bioscience share prices have been bracketed by a low of $3.45 and a high of $6.26 and closed yesterday at $4.47, 30% above that low price. The 200-day and 50-day moving averages have moved 0.29% lower and 1.21% lower over the past week, respectively.
Harvard Bioscience Announces Inducement Grants to Recently Hired Executives
GlobeNewswire - Mon Nov 18, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has granted the inducement stock option grants it was obligated to grant to its recently hired executives as follows:
Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard Apparatus Regenerative Technology
GlobeNewswire - Wed Nov 13, 10:29AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, announced the allocation of tax basis resulting from the tax-free spin-off of Harvard Apparatus Regenerative Technology, Inc. Based on the relative fair market values of the respective companies on November 1, 2013, the first day of trading after distribution, 23.63 percent of a stockholder`s pre-distribution tax basis in Harvard Bioscience common stock should be allocated to the shares of common stock in Harvard Apparatus Regenerative Technology received pursuant to the distribution described in the Information Statement of Harvard Apparatus Regenerative Technology dated October 17, 2013.
Harvard Bioscience Inc names Jeffrey A. Duchemin as new CEO
M2 - Wed Aug 28, 11:16AM CDT
Life science research company Harvard Bioscience Inc (NasdaqGM:HBIO) said on Tuesday that its board of directors has elected Jeffrey A. Duchemin as its new chief executive officer.
Harvard Bioscience Announces Jeffrey A. Duchemin as New CEO
GlobeNewswire - Tue Aug 27, 10:11AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that its Board of Directors has hired Jeffrey A. Duchemin, a veteran life science executive, as Harvard Bioscience's Chief Executive Officer. David Green, who has served as Harvard Bioscience's interim Chief Executive Officer since May 15, 2013, has resigned from that interim position and will continue in his capacity as the President of Harvard Bioscience until the completion of the Company's spin-off of its regenerative medicine subsidiary.
HBIO Reports Second Quarter 2013 Results
GlobeNewswire - Thu Aug 01, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial results for the three and six months ended June 30, 2013.
Harvard Bioscience, Inc. Schedules Second Quarter 2013 Conference Call for August 1, 2013
GlobeNewswire - Wed Jul 31, 5:33PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, will announce results for its second quarter ended June 30, 2013 before market trading hours on Thursday, August 1, 2013.
HBIO Subsidiary Harvard Apparatus Regenerative Technology, Inc. Files Form 10 Registration Statement for Planned Spin-Off
GlobeNewswire - Wed Jul 31, 4:32PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that its wholly-owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART, has filed an initial Form 10 Registration Statement ("Form 10"
with the U.S. Securities and Exchange Commission to separate the regenerative medicine device business from Harvard Bioscience's profitable core life science research tools business.
Global Transfection Technology (Reagent-based method, Instrument-based method and Virus-based method) Market - Forecast to 2019
M2 - Fri May 09, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h75tdm/transfection) has announced the addition of the "Transfection Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Transfection is a process that involves production of genetically modified cells with the delivery of foreign nucleic acid (DNA or RNA) into the cell. There are two types of transfection technologies that include stable and transient. While stable transfection is permanent and the genes are continually expressed even after the host cell replicates, transient transfected genes are expressed for a limited period of time and are not integrated into the host genome. Increasing prevalence of cancer and growing obese population drives the global transfection technology market. In addition, initiatives taken by various government organizations also further accentuates the growth of this market. Transfection technologymarket is segmented mainly by types of method and application. The method segment of the market is classified as reagent-based method, instrument-based method and virus-based method. The reagent-based method is further segmented as lipid mediated transfection (Lipofection), calcium phosphate, cationic polymers, DEAE-dextran, activated dendrimers and magnetic beads. Reagent based transfection technology market is experiencing significant growth owing to cost effectiveness and less complicated methods involved during transfection. Likewise, instrument-based method includes electroporation, biolistic technology, microinjection and laserfection.Instrument-based methods are less time consuming and accurate;these advantages drive the growth of this segment. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Transfection Technology Market, by Methods Chapter 5 Global Transfection Technology Market, By Application Chapter 6 Global Transfection Technology Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Bio-Rad Laboratories, Inc. - Harvard Bioscience, Inc. - Life Technologies Corporation - Lonza Group Ltd. - Merck KGaA - Mirus Bio LLC - Polyplus-transfection S.A. - Promega Corporation - QIAGEN - Roche Holding AG - Sigma-Aldrich Corporation - SignaGen Laboratories - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/h7...ansfection
Harvard Bioscience Reports First Quarter 2014 Results
GlobeNewswire - Thu May 01, 6:02AM CDT
Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today reported financial highlights for the three months ended March 31, 2014.
Electrophoresis Equipment and Supplies Market 2013-2019: Gel Electrophoresis, Capillary Electrophoresis and Electrophoresis Accessories Analysis
M2 - Wed Apr 30, 6:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xwbmkl/electrophoresis) has announced the addition of the "Electrophoresis Equipment and Supplies Market 2013-2019: Gel Electrophoresis, Capillary Electrophoresis and Electrophoresis Accessories Analysis" report to their offering. Electrophoresis is an analytical technique used to separate macromolecules such as nucleic acid fragments, proteins and RNA according to their molecular size and electric charge. Electrophoresis can be classified in two types gel electrophoresis and capillary electrophoresis. Electrophoresis clinical applications can be segmented as diagnostics (protein), hemoglobin analysis and microbial detection. This report studies the global market for electrophoresis equipment and supplies market along with its clinical applications. The market is thus segmented on the basis of technologies and applications. The market for electrophoresis equipment and supplies are also analyzed for four major geographic regions namely North America, Europe, Asia and the rest of the world (RoW) regions. The markets for all these segments is analyzed and estimated in USD million. Each of the segments has been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD million, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each market segment has been provided for the forecast period 2013 to 2019 along with the estimations of market size. A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for electrophoresis equipment and supplies market. A chapter on recommendations for existing and new entrants is also provided in this report. Some of the major players profiled in this report are BioRad Laboratories, Inc., GE Healthcare Ltd., Hoefer, Inc., Agilent Technologies, Life Technologies Corporation, Thermo Fisher Scientific, Inc. and Danaher Corporation. All these market players are profiled in this report via parameters such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Electrophoresis Equipment and Supplies Market, by Technology, 2013 - 2019 (USD Million) Chapter 5 Global Electrophoresis Equipment and Supplies Market, by Applications, 2013 - 2019 (USD Million) Chapter 6 Global Electrophoresis Equipment and Supplies Market, by Geography, 2013 - 2019 (USD Million) Chapter 7 Competitive Landscape Chapter 8 Recommendations Chapter 9 Company Profiles - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - GE Healthcare - Harvard Bioscience, Inc. - Helena Laboratories Corporation - Life Technologies Corporation - Lonza Group - Perkin Elmer, Inc. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/xw...rophoresis
Harvard Bioscience to Present at the Sidoti Micro-Cap Conference on May 9 in New York
GlobeNewswire - Wed Apr 23, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of solutions to advance life science, will present at the Sidoti Ninth Semiannual Micro-Cap Conference in New York City on May 9, 2014.
SeeThruEquity Issues Update on Harvard Bioscience Inc.
ACCESSWIRE - Thu Apr 17, 8:01AM CDT
New York, NY / ACCESSWIRE / April 17, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update note on Harvard Bioscience Inc. (NASDAQ: HBIO) regarding financial and operational results for Q4 2013 and FY 2013.
Harvard Bioscience Schedules First Quarter 2014 Conference Call for May 1, 2014 at 11:00 AM ET
GlobeNewswire - Thu Apr 17, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of solutions to advance life science, will announce results for its first quarter before market trading hours on Thursday, May 1, 2014. A conference call to discuss the company's first quarter is scheduled for that same day at 11:00 AM ET.
I’m Selling Harvard Biosciences
Jim Royal, The Motley Fool - Motley Fool - Thu Mar 27, 3:31PM CDT
My Special Situations portfolio took a stake in Harvard Bioscience before its recently completed spinoff of Harvard Apparatus Regenerative Technology . That was in January of last year, and the combined position has risen about 39%. Not bad....
Harvard Bioscience Names Ronald Aplin to Vice President Global Operations and Quality
GlobeNewswire - Mon Mar 10, 6:13AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has named Ronald Aplin to Vice President Global Operations and Quality, effective immediately. This is a newly created position.
Nasdaq stocks posting largest volume increases
AP - Mon Mar 03, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Harvard Bioscience Reports Fourth Quarter and Year-End 2013 Results
GlobeNewswire - Thu Feb 27, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of specialized products to advance life science research, today reported financial highlights for the fourth quarter and full year ended December 31, 2013.
Harvard Bioscience Schedules Fourth Quarter and Year-End 2013 Conference Call for February 27, 2014 at 11:00 AM ET
GlobeNewswire - Fri Feb 14, 6:30AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, will announce results for its fourth quarter and year ended December 31, 2013 before market trading hours on Thursday, February 27, 2014. A conference call to discuss the company's fourth quarter and year-end financial results is scheduled for that same day at 11:00 AM ET.
Harvard Bioscience Realigns Global Operations to Create Organizational Efficiencies and Better Position It for Growth
GlobeNewswire - Wed Dec 04, 6:00AM CST
-Reallocating Resources to Higher-Growth Areas-
Upgrade Alert for Harvard Bioscience (HBIO)
Comtex SmarTrend(R) - Wed Nov 27, 7:04AM CST
Harvard Bioscience (NASDAQ:HBIO) was upgraded from Neutral to Buy at Sidoti today. The stock closed yesterday at $4.47 on volume of 393,000 shares, above average daily volume of 202,000. In the past 52 weeks, Harvard Bioscience share prices have been bracketed by a low of $3.45 and a high of $6.26 and closed yesterday at $4.47, 30% above that low price. The 200-day and 50-day moving averages have moved 0.29% lower and 1.21% lower over the past week, respectively.
Harvard Bioscience Announces Inducement Grants to Recently Hired Executives
GlobeNewswire - Mon Nov 18, 6:00AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, has granted the inducement stock option grants it was obligated to grant to its recently hired executives as follows:
Harvard Bioscience Announces Allocation of Tax Basis for Spin-Off of Harvard Apparatus Regenerative Technology
GlobeNewswire - Wed Nov 13, 10:29AM CST
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, announced the allocation of tax basis resulting from the tax-free spin-off of Harvard Apparatus Regenerative Technology, Inc. Based on the relative fair market values of the respective companies on November 1, 2013, the first day of trading after distribution, 23.63 percent of a stockholder`s pre-distribution tax basis in Harvard Bioscience common stock should be allocated to the shares of common stock in Harvard Apparatus Regenerative Technology received pursuant to the distribution described in the Information Statement of Harvard Apparatus Regenerative Technology dated October 17, 2013.
Harvard Bioscience Inc names Jeffrey A. Duchemin as new CEO
M2 - Wed Aug 28, 11:16AM CDT
Life science research company Harvard Bioscience Inc (NasdaqGM:HBIO) said on Tuesday that its board of directors has elected Jeffrey A. Duchemin as its new chief executive officer.
Harvard Bioscience Announces Jeffrey A. Duchemin as New CEO
GlobeNewswire - Tue Aug 27, 10:11AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that its Board of Directors has hired Jeffrey A. Duchemin, a veteran life science executive, as Harvard Bioscience's Chief Executive Officer. David Green, who has served as Harvard Bioscience's interim Chief Executive Officer since May 15, 2013, has resigned from that interim position and will continue in his capacity as the President of Harvard Bioscience until the completion of the Company's spin-off of its regenerative medicine subsidiary.
HBIO Reports Second Quarter 2013 Results
GlobeNewswire - Thu Aug 01, 6:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial results for the three and six months ended June 30, 2013.
Harvard Bioscience, Inc. Schedules Second Quarter 2013 Conference Call for August 1, 2013
GlobeNewswire - Wed Jul 31, 5:33PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, will announce results for its second quarter ended June 30, 2013 before market trading hours on Thursday, August 1, 2013.
HBIO Subsidiary Harvard Apparatus Regenerative Technology, Inc. Files Form 10 Registration Statement for Planned Spin-Off
GlobeNewswire - Wed Jul 31, 4:32PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that its wholly-owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART, has filed an initial Form 10 Registration Statement ("Form 10"
with the U.S. Securities and Exchange Commission to separate the regenerative medicine device business from Harvard Bioscience's profitable core life science research tools business. 
